{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:03:43Z","timestamp":1747163023244,"version":"3.40.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.intimp.2024.112039","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T20:18:54Z","timestamp":1712953134000},"page":"112039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["High mobility group box 1 mediates inflammatory responses in malignant peritoneal mesothelioma"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5177-086X","authenticated-orcid":false,"given":"Lianfen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuesong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weili","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112039_b0005","doi-asserted-by":"crossref","first-page":"236","DOI":"10.21037\/atm.2017.03.96","article-title":"Malignant peritoneal mesothelioma: a review","volume":"5","author":"Kim","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.intimp.2024.112039_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010229","article-title":"Contemporary trends in malignant peritoneal mesothelioma: incidence and survival in the United States","volume":"15","author":"Calthorpe","year":"2022","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.intimp.2024.112039_b0015","doi-asserted-by":"crossref","first-page":"537","DOI":"10.21037\/tlcr.2018.10.04","article-title":"Malignant peritoneal mesothelioma: a review","volume":"7","author":"Broeckx","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.intimp.2024.112039_b0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.14735\/amko2019333","article-title":"Treatment of malignant peritoneal mesothelioma","volume":"32","author":"Levy","year":"2019","journal-title":"Klin Onkol"},{"key":"10.1016\/j.intimp.2024.112039_b0025","first-page":"659","article-title":"Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives","volume":"31","author":"Boussios","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.intimp.2024.112039_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030662","article-title":"Diagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma","volume":"15","author":"Kusamura","year":"2023","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.intimp.2024.112039_b0035","doi-asserted-by":"crossref","first-page":"599","DOI":"10.21037\/tlcr.2018.08.03","article-title":"Update on the management of malignant peritoneal mesothelioma","volume":"7","author":"Sugarbaker","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.intimp.2024.112039_b0040","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.12688\/f1000research.15512.2","article-title":"Factors influencing malignant mesothelioma survival: a retrospective review of the national mesothelioma virtual bank cohort","volume":"7","author":"Amin","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.intimp.2024.112039_b0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbagrm.2009.11.014","article-title":"High-mobility group box 1 and cancer","volume":"1799","author":"Tang","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.intimp.2024.112039_b0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2119\/2008-00034.Klune","article-title":"HMGB1: endogenous danger signaling","volume":"14","author":"Klune","year":"2008","journal-title":"Mol Med"},{"key":"10.1016\/j.intimp.2024.112039_b0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejphar.2017.01.019","article-title":"Ilexgenin a, a novel pentacyclic triterpenoid extracted from aquifoliaceae shows reduction of LPS-induced peritonitis in mice","volume":"797","author":"Sun","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112039_b0060","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10072-019-04136-3","article-title":"HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis","volume":"41","author":"Bucova","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1016\/j.intimp.2024.112039_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-020-00920-3","article-title":"High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies","volume":"13","author":"Yuan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2024.112039_b0070","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-13-0495","article-title":"HMGB1 in cancer: good, bad, or both?","volume":"19","author":"Kang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.112039_b0075","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/MCG.0b013e318297fa65","article-title":"Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma","volume":"47","author":"Tabata","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.intimp.2024.112039_b0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/00365513.2023.2168213","article-title":"Correlation of serum-soluble mesothelin-related protein, HMGB1 and CA125 in diffuse malignant peritoneal mesothelioma and their combined measurement for prognosis","volume":"83","author":"Wang","year":"2023","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.intimp.2024.112039_b0085","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","article-title":"Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma","volume":"72","author":"Jube","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.intimp.2024.112039_b0090","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111946118","article-title":"BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene x environment interaction with asbestos","volume":"118","author":"Novelli","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2024.112039_b0095","doi-asserted-by":"crossref","first-page":"22649","DOI":"10.18632\/oncotarget.15152","article-title":"HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma","volume":"8","author":"Pellegrini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2024.112039_b0100","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.153","article-title":"Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.intimp.2024.112039_b0105","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1122860","article-title":"Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis","volume":"5","author":"Cottone","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2024.112039_b0110","article-title":"HMGB1 as a potential biomarker and therapeutic target for malignant mesothelioma","author":"Wang","year":"2019","journal-title":"Dis Markers"},{"key":"10.1016\/j.intimp.2024.112039_b0115","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci. U S A"},{"key":"10.1016\/j.intimp.2024.112039_b0120","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci. U S A"},{"key":"10.1016\/j.intimp.2024.112039_b0125","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307999120","article-title":"HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma","volume":"120","author":"Suarez","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2024.112039_b0130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2119\/molmed.2013.00164","article-title":"The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases","volume":"20","author":"Magna","year":"2014","journal-title":"Mol Med"},{"key":"10.1016\/j.intimp.2024.112039_b0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-020-00950-x","article-title":"HMGB1 in inflammation and cancer","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2024.112039_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.1104648","article-title":"The cytokine activity of HMGB1","volume":"78","author":"Yang","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2024.112039_b0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","article-title":"The mechanism of HMGB1 secretion and release","volume":"54","author":"Chen","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2024.112039_b0150","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.20111739","article-title":"HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4","volume":"209","author":"Schiraldi","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2024.112039_b0155","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/08916934.2012.750302","article-title":"During apoptosis HMGB1 is translocated into apoptotic cell-derived membranous vesicles","volume":"46","author":"Schiller","year":"2013","journal-title":"Autoimmunity"},{"key":"10.1016\/j.intimp.2024.112039_b0160","doi-asserted-by":"crossref","first-page":"C1318","DOI":"10.1152\/ajpcell.00616.2005","article-title":"The extracellular release of HMGB1 during apoptotic cell death","volume":"291","author":"Bell","year":"2006","journal-title":"American J. physiology-cell Physiology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924005575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924005575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T20:04:42Z","timestamp":1715630682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924005575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":32,"alternative-id":["S1567576924005575"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112039","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High mobility group box 1 mediates inflammatory responses in malignant peritoneal mesothelioma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112039"}}